9 results found.

Recurrent Adult Hodgkin Lymphoma Clinical Trial using temsirolimus; brentuximab vedotin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma.
temsirolimus; brentuximab vedotin; laboratory biomarker analysis

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using ipilimumab; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma.
ipilimumab; rituximab; laboratory biomarker analysis

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non Clinical Trial using autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years or older.
- Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma.
autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Recurrent Adult Hodgkin Lymphoma, or Recurrent/Refractory Childho Clinical Trial using brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 13 Months to 30 years.
- A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND# 117117) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma.
brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.
alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; bortezomib; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma.
alisertib; bortezomib; rituximab; laboratory biomarker analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using alisertib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma.
alisertib; pharmacological study; laboratory biomarker analysis

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Pre Clinical Trial using panobinostat; lenalidomide

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma.
panobinostat; lenalidomide

Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Fo Clinical Trial using PI3K inhibitor BKM120; laboratory biomarker analysis

Mayo Clinic - Recruiting 18 years or older.
- A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma.
PI3K inhibitor BKM120; laboratory biomarker analysis